1.
Fonseca PEO, Azevedo JA, BiƩ SMG, Ferreira SB. Benefits of using SLGT2 Inhibitors for Patients with CDK and DM2 to Reduce Mortality Risks. Arch Pharm Pharma Sci [Internet]. 2024 May 2 [cited 2025 Oct. 4];8(1):041-6. Available from: https://www.pharmacyscijournal.com/apps/article/view/apps-aid1055